Alumni Ventures Group
Alumni Ventures Group is a venture capital firm based in Manchester, New Hampshire, with offices across North America. It provides access to venture investing for individual accredited investors, particularly alumni networks, by offering diversified portfolios of venture opportunities and allowing members to invest alongside fellow alumni in ventures led by peers. The firm backs early-stage and later-stage opportunities across technology, consumer, healthcare, financial services, and other sectors, with a sector- and geography-agnostic approach. It typically invests between $10,000 and $3 million per deal and emphasizes the involvement of alumni connections and an institutional lead investor in opportunities. Alumni Ventures also offers focused funds to broaden participation, enabling accredited investors to access venture portfolios diversified by type, sector, stage, and geography. The model aims to democratize access to venture capital while maintaining rigorous selection standards through alumni networks.
Top Sectors
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Therapeutics
Salvo Health
Seed Round in 2025
Salvo Health is a specialty care provider operating an app-based virtual clinic focused on managing chronic gut conditions. The company improves access to advanced healthcare by employing its proprietary Whole Self Science model, which considers overall health and contributing factors beyond the gut to pinpoint underlying causes and offer individualized, ongoing treatment strategies for patients with chronic gastrointestinal issues.
Kindbridge Behavioral Health
Pre Seed Round in 2024
Kindbridge Behavioral Health provides individual therapy, family therapy, group services, pricing, and insurance services. They provide treatments for depression, anxiety, gaming, stress, relationships, PTSD, family conflicts, mood disorders, gambling, trauma, addiction, dissociative disorders, and ADHD.
InGel Therapeutics
Seed Round in 2024
InGel Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2021. The company focuses on developing engineered cell therapies aimed at targeting neuroprotective pathways to address retinal degeneration. Utilizing stem cells and their secretome, InGel Therapeutics aims to provide neuroprotection for blinding diseases such as retinitis pigmentosa and macular degeneration. The company leverages biodegradable polymers to isolate neuroprotective proteins, initially testing these solutions in vitro before advancing to in vivo applications. Through its innovative approach, InGel Therapeutics seeks to enable healthcare professionals to more effectively treat patients suffering from retinal degeneration.
Magnetic Insight
Series B in 2024
Magnetic Insight, Inc. is a company specializing in magnetic particle imaging (MPI), an innovative imaging modality that detects iron oxide nanoparticle tracers through time-varying magnetic fields. Founded in 2012 and headquartered in Alameda, California, the company offers several key products, including the MOMENTUM imager, a pre-clinical MPI solution designed to produce high-quality images using advanced magnetic field gradients and proprietary reconstruction processes. Additionally, Magnetic Insight develops VivoTrax, a nanoparticle for cell tracking and as a blood pool agent, and Hyper, an add-on module for the MOMENTUM system that facilitates targeted magnetic hyperthermia treatment. The company's technology enables real-time monitoring of biological events, making significant strides in areas such as quantitative cell tracking, imaging of vascular function, and research into regenerative medicine and CAR-T cell therapies.
Leo Cancer Care
Series C in 2024
Leo Cancer Care develops an integrated cancer treatment system designed to simplify radiation therapy and improve patient experience. Founded in Australia, the company promotes upright patient positioning and a shift from machine rotation to patient rotation, supported by global research on its clinical benefits. The system combines three-dimensional imaging with automated control of radiation beams to deliver the appropriate energy to the targeted tissue, enabling radiotherapy centers to reduce pain, time, and cost. It can be integrated with standard radiotherapy equipment to support image-guided delivery and streamlined workflows. By prioritizing patient positioning and precise dose delivery, Leo Cancer Care aims to improve treatment accuracy, accessibility, and safety in cancer care.
ParcelBio
Seed Round in 2024
ParcelBio is a biotechnology company specializing in the development of a novel, programmable method for safely and precisely delivering messenger RNA (mRNA) to diverse cell types within the body. Their technology aims to create targeted, potent, and durable RNA therapeutics, with the potential to treat a wide range of diseases, including cancer, genetic disorders, and infectious diseases.
Iambic
Series B in 2024
Iambic Therapeutics focuses on accelerating molecular discovery through its innovative quantum molecular simulation engine. By integrating artificial intelligence and automated synthetic development, the company aims to enhance the design of small-molecule therapeutics. This technology significantly improves the accuracy of molecular predictions, providing valuable insights for therapeutic discovery. Iambic Therapeutics is committed to transforming the drug development process, enabling physicians to access more precise molecular data and ultimately improving treatment outcomes.
Nectero Medical
Series D in 2024
Nectero Medical is a clinical-stage biotechnology company based in Dover, Delaware, founded in 2017. The company is focused on developing a novel treatment aimed at stabilizing the growth of mid-sized abdominal aortic aneurysms and preventing their rupture. Nectero Medical's innovative approach involves delivering a compound with a stabilizing agent directly to the aneurysm site, which inhibits further breakdown of the vessel wall and strengthens it. This treatment enables patients to undergo earlier intervention safely, potentially delaying or eliminating the need for major endovascular or surgical repairs.
HelixNano
Series A in 2024
HelixNano is a biotechnology startup that employs artificial intelligence and synthetic biology to develop innovative treatments for genetic diseases. Founded with backing from Y Combinator and venture capitalists, the company initially focused on creating cancer vaccines over two years. Currently, HelixNano is adapting its technology to combat COVID-19, aiming to produce precise and safe vaccine candidates. Its long-term goal is to develop a universal coronavirus vaccine that protects against future outbreaks.
Pi Health
Series A in 2024
Pi Health is a technology company specializing in streamlining oncology clinical trials. It offers a global, secure, and compliant platform that integrates various systems, enabling life sciences companies to identify suitable trial sites, manage them efficiently, and accelerate the development of lifesaving medicines. This, in turn, enhances patient access to cancer care and research, and facilitates the inclusion of diverse patient populations in clinical trials.
BE Therapeutics
Seed Round in 2024
BE Therapeutics is a biotechnology company specializing in regenerative medicine. It develops innovative therapies aimed at repairing and restoring damaged brain and spinal cord tissue, with the goal of improving patient outcomes for neurological conditions and spinal cord injuries. The company's approach involves engineering functional tissue to replace or repair damaged structures, offering a novel solution in healthcare.
Cyrus Biotechnology
Series B in 2024
Founded in 2014, Cyrus Biotechnology develops software tools for accelerating basic research in biotech, pharma, and industrial biotechnology. Its flagship product, Cyrus Bench, offers an enterprise version of the Rosetta molecular modeling and design toolkit along with associated bio-molecular computation tools.
Pendulum Therapeutics
Series C in 2024
Pendulum Therapeutics is a biotechnology company specializing in microbiome-targeted therapies. Founded in 2013 by experts in microbiology, biochemistry, computational science, and clinical research, the company develops evidence-based medical probiotics to manage chronic illnesses, with a focus on type 2 diabetes. Its flagship product, Pendulum Glucose Control, has demonstrated efficacy in lowering blood sugar spikes and reducing A1C levels in clinical trials.
Granata Bio
Series A in 2024
Granata Bio is a biotechnology company established in 2018 that specializes in identifying and developing therapeutics for fertility patients. The company focuses on creating a comprehensive portfolio of fertility-related treatments and leverages its expertise in commercialization, late-stage clinical trials, and regulatory development. Granata Bio aims to address significant challenges faced by medical professionals in fertility treatment. Recently, the company announced a partnership with IBSA Institut Biochimique to co-develop a novel subcutaneous progesterone solution, further enhancing its commitment to improving fertility care.
Earli
Series A in 2024
Earli is a biotechnology company focused on advancing cancer detection and treatment through innovative technology. The company specializes in developing devices that utilize a novel gene therapy approach known as Synthetic Biopsy. This method compels cancer cells to produce synthetic biomarkers, which are not naturally occurring in the human body. These biomarkers can then be detected in bodily fluids such as blood, urine, or breath, allowing for early identification of cancer. By facilitating the early detection of homogeneous tumors, Earli aims to significantly improve the chances of successful treatment and personalize therapy options for patients. Additionally, the technology is designed to be visible during imaging procedures such as PET scans, enhancing the monitoring of cancer progression and treatment efficacy.
Eigen Therapeutics
Seed Round in 2023
Eigen Therapeutics is a biotechnology company dedicated to advancing cancer treatment through the development of innovative therapies. It specializes in "priming" therapies that enhance the effectiveness of targeted treatments by addressing cancer heterogeneity, which makes cancer cells more susceptible to therapeutic interventions while simultaneously protecting healthy cells. Eigen is creating a high-throughput discovery platform that integrates proprietary machine learning algorithms to identify novel drug classes and therapeutic approaches capable of altering a cell’s state to increase vulnerability to treatments. This platform combines biology and engineering, utilizing in-house developed robotic systems, laboratory operations software, and machine learning analysis pipelines. The company's mission focuses on improving patient outcomes by providing novel combination therapeutics that enhance efficacy and reduce toxicity in cancer care, ultimately aiming to meet significant medical needs in oncology.
TFC Therapeutics
Pre Seed Round in 2023
TFC Therapeutics is a biotechnology company focused on creating innovative biologics aimed at addressing critical factors in cancer recurrence and metastasis. The company develops technology that employs monoclonal antibodies designed to specifically bind to receptors on tumor-initiating cells, known as TMH cells. This targeted approach activates the immune system to effectively destroy these cells, offering new treatment possibilities for cancer within the healthcare sector. Through its research and development efforts, TFC Therapeutics seeks to contribute significantly to advancements in cancer therapy.
Ossium Health
Series C in 2023
Ossium Health, Inc. is a biotechnology company that specializes in developing and manufacturing advanced cell therapy products aimed at treating blood cancers, improving organ transplantation, and repairing tissue damage caused by radiation exposure. Established in 2016 and based in San Francisco, the company has created a range of therapies, including HPC, Marrow, which consists of human leukocyte antigen (HLA)-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients. Additionally, Ossium offers Chimera, designed to enhance organ transplantation, and Chymalis, which utilizes mesenchymal stem cells from bone marrow to facilitate the healing of damaged bone and muscle tissue. The company also supplies bone marrow cells for research in oncology, immunology, and related fields, focusing on improving health and longevity through innovative bioengineering techniques.
Oliva Health
Seed Round in 2023
Oliva Therapy is an online mental healthcare platform based in Barcelona, Spain, founded in 2020. It aims to make mental healthcare accessible, uncomplicated, and stigma-free for busy individuals. The platform allows users to book one-hour therapy sessions via real-time video calls with expert-curated therapists, who are matched to users based on their specific needs. By simplifying the process of seeking therapy, Oliva helps working professionals achieve their mental health goals while maintaining a better work-life balance. The focus on personalized matching and a hassle-free online experience distinguishes Oliva in the mental health sector.
Iolyx Therapeutics
Series A in 2023
Iolyx Therapeutics is a biotechnology company focused on ocular diseases, developing immunology-driven therapies for ophthalmology and advancing a platform for tailored formulations that enable precise local delivery of immunological drugs to ocular tissues, targeting inflammation at its source in both the anterior and posterior segments to improve efficacy, safety, and patient convenience.
Dimension Inx
Series A in 2023
Dimension Inx designs and develops advanced biomaterials for regenerative medicine. Founded in 2017, it specializes in creating microenvironments that guide the body's natural healing processes. Its platform focuses on the interplay between material composition, microstructure, and microarchitecture to produce biofunctional materials.
Eigen Therapeutics
Seed Round in 2022
Eigen Therapeutics is a biotechnology company dedicated to advancing cancer treatment through the development of innovative therapies. It specializes in "priming" therapies that enhance the effectiveness of targeted treatments by addressing cancer heterogeneity, which makes cancer cells more susceptible to therapeutic interventions while simultaneously protecting healthy cells. Eigen is creating a high-throughput discovery platform that integrates proprietary machine learning algorithms to identify novel drug classes and therapeutic approaches capable of altering a cell’s state to increase vulnerability to treatments. This platform combines biology and engineering, utilizing in-house developed robotic systems, laboratory operations software, and machine learning analysis pipelines. The company's mission focuses on improving patient outcomes by providing novel combination therapeutics that enhance efficacy and reduce toxicity in cancer care, ultimately aiming to meet significant medical needs in oncology.
Axoft
Seed Round in 2022
Axoft develops implantable, bioinspired electronics that enable long-term communication with the nervous system to improve clinical outcomes and overall health. The company creates ultra-flexible plastic mesh implants housing multiple sensors that closely match brain tissue mechanics, aiming to reduce tissue response and enable precise monitoring and intervention for neurodegenerative conditions. By enhancing brain–machine communication, Axoft seeks to provide more effective treatments for patients with Parkinson's disease and related disorders, supporting tailored therapies and better patient outcomes.
Surge Therapeutics
Series A in 2022
SURGE Therapeutics is a biotechnology company focused on enhancing cancer treatment outcomes through innovative immunotherapy solutions. It has developed a proprietary injectable biodegradable hydrogel designed to deliver cancer therapeutics in a prolonged and localized manner. This technology enables targeted release of immunotherapy agents at the surgical site following tumor resection, allowing for more effective treatment administration. By optimizing the timing and location of drug delivery, SURGE Therapeutics aims to improve patient survival rates and minimize systemic side effects, representing a significant advancement in the field of cancer care.
Brave Health
Series C in 2022
Brave Health is a virtual clinic that provides telehealth services focused on mental health and addiction treatment. Established in 2017 by Anna Lindow in Miami, Florida, the company specializes in behavioral health, offering a range of services including counseling, therapy, psychiatry, and medication management. This includes medication-assisted treatment, allowing patients to receive comprehensive care for various conditions related to mental health and substance use disorders. By leveraging telehealth technology, Brave Health enables patients to access essential services conveniently and efficiently, addressing the growing need for accessible mental health care.
Magnetic Insight
Series B in 2022
Magnetic Insight, Inc. is a company specializing in magnetic particle imaging (MPI), an innovative imaging modality that detects iron oxide nanoparticle tracers through time-varying magnetic fields. Founded in 2012 and headquartered in Alameda, California, the company offers several key products, including the MOMENTUM imager, a pre-clinical MPI solution designed to produce high-quality images using advanced magnetic field gradients and proprietary reconstruction processes. Additionally, Magnetic Insight develops VivoTrax, a nanoparticle for cell tracking and as a blood pool agent, and Hyper, an add-on module for the MOMENTUM system that facilitates targeted magnetic hyperthermia treatment. The company's technology enables real-time monitoring of biological events, making significant strides in areas such as quantitative cell tracking, imaging of vascular function, and research into regenerative medicine and CAR-T cell therapies.
Swing Therapeutics
Series A in 2022
Swing develops safe and effective digital therapeutics for chronic conditions, partnering with top researchers to create evidence-based treatments. Their solutions empower patients to manage their illnesses, improving health outcomes.
Boulder Care
Series B in 2022
Boulder Care, established in 2017 and headquartered in Portland, Oregon, specializes in telemedicine-based programs for opioid addiction treatment. The company offers comprehensive services including medication-assisted treatment with buprenorphine, peer support, patient counseling, and psychosocial services to aid recovery. Boulder Care serves patients directly, as well as healthcare providers and organizations seeking to expand access to effective opioid addiction treatment.
American Gene Technologies International
Series D in 2022
American Gene Technologies International is a gene and cell therapeutics company developing a lentiviral platform for broad applications across infectious diseases, immuno-oncology, monogenic disorders, and regenerative medicine. It pursues HIV cure strategies, including a lead candidate for functional cure, and an immuno-oncology approach that stimulates gamma-delta T cells to target solid tumors. The company also develops a therapeutic approach for Phenylketonuria by expressing phenylalanine hydroxylase, using proprietary viral vector and gene therapy technologies. Founded in 2007 and based in Rockville, Maryland, AGT focuses on translating its platform into therapies that aim to cure diseases rather than merely treat them.
Concerto Biosciences
Venture Round in 2022
Concerto Biosciences develops microbe-based products that rebuild microbial communities in and around humans and ecosystems. The company uses an ultra-high-throughput platform to experimentally measure millions of microbial interactions and map interaction networks, enabling the discovery of ensembles, which are specific combinations of microbes that work together to shepherd damaged microbial communities back to health. These ensembles have potential applications across medicine and agriculture, addressing global challenges in health, food, and industry. By focusing on microbial community engineering, Concerto aims to become a leading inventor of ensembles and to redefine how microbiomes are leveraged for health and environmental outcomes.
Satellite Bio
Series A in 2022
Satellite Bio develops cell therapies and regenerative medicine approaches, spanning cell biology, tissue engineering, and synthetic biology. The company focuses on proprietary, off-the-shelf implantable satellite organs that function as living therapeutic systems to replace or augment critical organ functions in patients with serious diseases, enabling medical professionals to address conditions arising from genetic and environmental factors. Its platform supports the development of modular, scalable therapies aimed at treating complex diseases and transforming patient outcomes.
Droplette
Series B in 2021
Droplette Inc., founded in 2017 and based in Boston, Massachusetts, specializes in innovative skincare technology through its needle-free device designed for the transdermal delivery of active ingredients. This patent-pending system allows for the administration of drugs significantly larger than those achievable with traditional methods, ensuring deep penetration into the skin over large areas. The painless, contact-free device generates no disposables, offering a portable solution for delivering antibiotics to treat serious skin ulcers and infections, thereby minimizing the risks of secondary complications and antibiotic resistance. Additionally, the company is exploring future applications for localized delivery of chemotherapeutics for skin cancer and anti-aging treatments, aiming to enhance skincare routines while avoiding harmful chemicals.
Transcend Therapeutics
Series A in 2021
Transcend Therapeutics, Inc., established in 1992 in Waltham, Massachusetts, is a clinical-stage company focused on developing pharmaceuticals to address diseases associated with oxidative stress and tissue damage. The company also specializes in creating psychoactive medicines aimed at treating neuropsychiatric disorders. By targeting specific areas of the brain involved in the pathophysiology of these conditions, Transcend Therapeutics aims to enable healthcare providers to facilitate positive changes in brain function and behavior for their patients.
GRO Biosciences
Series A in 2021
GRO Biosciences employs computational protein design and synthetic biology to enhance protein therapeutics. It has developed multiple genomically recoded bacterial strains capable of incorporating non-standard amino acids into proteins, resulting in improved potency, stability, and targeted delivery. The company focuses on developing advanced treatments for diabetes, growth disorders, and autoimmunity.
Cellibre
Series A in 2021
Cellibre, Inc. is a cellular agriculture company founded in 2017 and headquartered in San Diego, California. The company focuses on transforming cells into specialized, sustainable factories to produce significant biological products at scale. Employing an organism-agnostic approach, Cellibre develops natural medicines by leveraging the naturopathic therapies of various cultures, as well as utilizing resources from plants, animals, insects, and marine life. This innovative method enables the healthcare industry to produce cannabinoid-based medicines aimed at providing efficient treatment options.
Blue Note Therapeutics
Series A in 2021
Blue Note Therapeutics is a prescription digital therapeutics company that develops software-driven mental health solutions and collaborates with medical researchers and patient advocacy organizations to provide physician-prescribed therapies accessible on mobile devices. Its platform delivers evidence-based interventions designed to prevent, manage, and treat mental health conditions associated with serious illnesses, including cancer, and can be used as first-line or adjuvant therapies. The company is based in San Francisco, California, and was founded in 2018.
Pocket Naloxone Corp.
Venture Round in 2021
Pocket Naloxone develops innovative naloxone formulations for improved overdose reversal. Its mission is to make naloxone more accessible and affordable, contributing to the reduction of opioid overdose fatalities.
Woebot Health
Series B in 2021
Woebot Health is a digital mental healthcare provider that offers a platform designed to deliver personalized support and guidance. Utilizing advanced artificial intelligence and natural language processing, Woebot Health incorporates clinically proven therapeutic techniques into its services. The centerpiece of its offering is Woebot, an engaging relational agent that facilitates continuous, empathic, and user-friendly interactions. This innovative approach allows individuals and organizations to access effective mental health support seamlessly, fitting into daily life and providing help whenever needed. Woebot Health aims to enhance mental well-being through scalable digital tools, making mental health resources more accessible to a broad audience.
Asto CT
Series B in 2021
Asto CT is a veterinary imaging company that develops X-ray computed tomography systems for horses, enabling safe, weight-bearing 3D imaging to diagnose and monitor conditions such as lameness, distal limb disease, fractures, and tooth or sinus problems. Its Equina solution provides rapid 3D scans of the lower limbs, head, and neck in standing horses without general anesthesia, supporting early detection and improved treatment planning for Thoroughbreds, other sport and recreation horses, and older animals. The company emphasizes high-quality imaging, ease of use, and integration of advanced robotics with fan-beam CT technology to enhance diagnostic capability and veterinary care. Founded in 2015 and based in Madison, Wisconsin, Asto CT aims to improve horse welfare by enabling safer, more accurate assessment while minimizing anesthesia risks.
Leo Cancer Care
Series B in 2021
Leo Cancer Care develops an integrated cancer treatment system designed to simplify radiation therapy and improve patient experience. Founded in Australia, the company promotes upright patient positioning and a shift from machine rotation to patient rotation, supported by global research on its clinical benefits. The system combines three-dimensional imaging with automated control of radiation beams to deliver the appropriate energy to the targeted tissue, enabling radiotherapy centers to reduce pain, time, and cost. It can be integrated with standard radiotherapy equipment to support image-guided delivery and streamlined workflows. By prioritizing patient positioning and precise dose delivery, Leo Cancer Care aims to improve treatment accuracy, accessibility, and safety in cancer care.
Cyrus Biotechnology
Venture Round in 2021
Founded in 2014, Cyrus Biotechnology develops software tools for accelerating basic research in biotech, pharma, and industrial biotechnology. Its flagship product, Cyrus Bench, offers an enterprise version of the Rosetta molecular modeling and design toolkit along with associated bio-molecular computation tools.
SHINE
Series C in 2021
SHINE develops and deploys fusion-based technology to produce medical isotopes and neutron sources. Its processes generate molybdenum-99, a precursor to technetium-99m used in diagnostic imaging, and lutetium-177 for diagnostic and therapeutic use, along with iodine-131 and iodine-125 for thyroid treatment and brachytherapy, and xenon-133 for lung and brain imaging. The company’s systems also provide neutron sources for industrial imaging, radiation-effects testing, and fusion materials research. In addition to medical isotopes, SHINE aims to recycle nuclear waste and advance fusion power as a source of clean energy. The business serves health care and industrial customers worldwide. SHINE is based in Janesville, Wisconsin, with an office in Alkmaar, Netherlands.
Veralox Therapeutics
Series A in 2021
Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.
miRecule
Venture Round in 2021
miRecule is a biotechnology company developing targeted RNA therapies for cancer and muscular dystrophy. It uses its proprietary DREAmiR platform to analyze genomic data from thousands of patients, identifying genetic abnormalities and creating tailored RNA therapeutics to directly address these issues.
Scipher Medicine
Series C in 2021
Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.
InteRNA Technologies
Series B in 2021
InteRNA Technologies B.V. is a biotechnology company focused on developing microRNA (miRNA)-based therapeutics for cancer treatment. Founded in 2006 and headquartered in Nijmegen, the Netherlands, with a research and development center in Utrecht, the company leverages its proprietary technology to discover and validate miRNA sequences that can target multiple signaling pathways involved in cancer initiation, progression, and metastasis. By addressing previously undruggable targets, InteRNA aims to enhance the efficacy of existing cancer therapies and reduce the development of drug resistance. The company employs advanced bioinformatics and massively parallel sequencing techniques to analyze miRNA functions, paving the way for innovative treatment options in oncology.
STIMIT
Venture Round in 2020
STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company specializes in developing innovative therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. STIMIT's proprietary technology non-invasively activates the body's own diaphragm, which is often weakened in such patients. By strengthening diaphragm function, the company seeks to facilitate the liberation of patients from ventilators, thereby reducing the time spent on ventilation and improving overall patient outcomes. Additionally, STIMIT is working on second-generation therapies that aim to further enhance the inhalation process for patients. Through these advancements, STIMIT is positioned to significantly impact intensive care practices and improve the quality of life for patients with respiratory challenges.
Concerto Biosciences
Seed Round in 2020
Concerto Biosciences develops microbe-based products that rebuild microbial communities in and around humans and ecosystems. The company uses an ultra-high-throughput platform to experimentally measure millions of microbial interactions and map interaction networks, enabling the discovery of ensembles, which are specific combinations of microbes that work together to shepherd damaged microbial communities back to health. These ensembles have potential applications across medicine and agriculture, addressing global challenges in health, food, and industry. By focusing on microbial community engineering, Concerto aims to become a leading inventor of ensembles and to redefine how microbiomes are leveraged for health and environmental outcomes.
Generate Biomedicines
Venture Round in 2020
Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.
SHINE
Venture Round in 2020
SHINE develops and deploys fusion-based technology to produce medical isotopes and neutron sources. Its processes generate molybdenum-99, a precursor to technetium-99m used in diagnostic imaging, and lutetium-177 for diagnostic and therapeutic use, along with iodine-131 and iodine-125 for thyroid treatment and brachytherapy, and xenon-133 for lung and brain imaging. The company’s systems also provide neutron sources for industrial imaging, radiation-effects testing, and fusion materials research. In addition to medical isotopes, SHINE aims to recycle nuclear waste and advance fusion power as a source of clean energy. The business serves health care and industrial customers worldwide. SHINE is based in Janesville, Wisconsin, with an office in Alkmaar, Netherlands.
Better Life Partners
Series A in 2020
Better Life Partners Inc. is a healthcare company based in Hanover, New Hampshire, dedicated to providing comprehensive support for individuals struggling with opioid use disorder in the United States. Established in 2018, the company offers a range of services, including medication-assisted treatment, counseling, peer coaching, and group sessions. Better Life Partners focuses on delivering personalized healthcare to vulnerable populations, utilizing technology to create customizable care plans that ensure effective and reliable service delivery. By integrating medical and behavioral healthcare, the company addresses the needs of those affected by addiction, facilitating their recovery through a combination of telehealth, community-based support, and innovative care approaches. With additional offices across New Hampshire, Better Life Partners aims to make a meaningful impact on the lives of individuals seeking to overcome substance abuse challenges.
Mission Bio
Venture Round in 2020
Mission Bio develops and delivers tools for studying cellular heterogeneity in human health and life science research. Its flagship product is the Tapestri Platform, a single-cell platform that detects DNA and protein changes, enabling precise detection of heterogeneity in disease progression and treatment response. The company's solutions are primarily applied in oncology, including blood cancers and solid tumors.
Gallant Pet
Venture Round in 2020
Gallant Pet, Inc. is a pet service company based in San Diego, California, that specializes in stem cell preservation services for pets. Founded in 2018 by Aaron Hirschhorn, the company collects and banks stem cells from tissue during routine spay or neuter procedures. Gallant Pet also provides a platelet-rich plasma (PRP) kit for treatment of dogs suffering from osteoarthritis or other musculoskeletal conditions. In addition to its preservation services, Gallant Pet is involved in clinical research to develop effective stem cell therapies for pets. The company's focus on retrieving and preserving regenerative cells allows pet owners to utilize their pets' young stem cells for potential treatments when needed.
Excision BioTherapeutics
Venture Round in 2019
Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company is dedicated to the development and commercialization of gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company's mission is to advance these therapeutics into safe and effective treatments, significantly improving the lives of individuals affected by viral infections globally.
SQZ Biotech
Series D in 2019
SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, the company can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide range of clinical challenges. SQZ Biotech aims to create well-tolerated and effective cell therapies that enhance patient experiences compared to traditional approaches. With its commitment to internal research and strategic partnerships, SQZ is working to advance a new generation of cell therapies through both immune activation and immune suppression methods, showcasing its potential to transform treatment options for patients.
miRecule
Venture Round in 2019
miRecule is a biotechnology company developing targeted RNA therapies for cancer and muscular dystrophy. It uses its proprietary DREAmiR platform to analyze genomic data from thousands of patients, identifying genetic abnormalities and creating tailored RNA therapeutics to directly address these issues.
Meditrina
Venture Round in 2019
Meditrina, Inc. is a medical device company based in San Jose, California, established in 2016. The company specializes in developing innovative tissue removal solutions specifically designed for intrauterine pathology. Its flagship product, the Aveta System, serves healthcare professionals by providing an all-in-one solution for hysteroscopic diagnostic and therapeutic procedures, such as the removal of polyps and fibroids. The Aveta System is notable for its compact design, which allows for seamless integration into various clinical settings, including offices and operating rooms. It features advanced capabilities such as wide-angle HD hysteroscopy, improved fluid management for better pressure control, and a small insertion diameter coupled with a large working channel, all of which contribute to optimized tissue resection and enhanced procedural efficiency.
Scipher Medicine
Series B in 2019
Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.
StemoniX
Series B in 2019
StemoniX Inc. is a biotechnology company that specializes in stem cell technologies aimed at advancing drug discovery and personalized medicine. Founded in 2014 and headquartered in Minneapolis, Minnesota, with an additional office in La Jolla, California, StemoniX offers a proprietary platform that facilitates the creation and scaling of human tissue derived from stem cells. This platform supports the 3-D printing of living cells for various applications, including research into heart disease, dementia, breast cancer, autism, and ALS. By operationalizing human-induced pluripotent stem cell (iPSC) disease models at scale, StemoniX enhances the efficiency of neurotoxicity research and drug screening, enabling scientists to conduct more effective studies with improved outcomes.
NeuSpera Medical
Series B in 2019
NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.
Mitra Biotech
Series C in 2018
Mitra Biotech, established in 2010, is a biotechnology company based in Woburn, Massachusetts, with a laboratory office in Bengaluru, India. It specializes in personalized cancer treatment, offering a novel functional assay called CANScript. This assay replicates a patient's tumor microenvironment, measures multiple parameters, and converts them into a single score predicting clinical response to selected therapies. Mitra Biotech's technology aids biopharma companies in drug discovery and development, expanding access to personalized medicine and enhancing cancer treatment selection.
Farcast
Series C in 2018
Farcast Biosciences, established in 2019, is a clinical diagnostic company based in Boston, Massachusetts, with operations in Bangalore, India. The company specializes in developing and utilizing a proprietary Human Tumor Micro Dynamics (HTMD) platform. This platform preserves the natural state of human tumors through the culture of fresh, unmodified tumor fragments, creating a human tumor microenvironment. Farcast's technology enables oncologists to evaluate individual tumors and predict patient response to treatments before initiating therapy. Additionally, it serves drug developers and researchers by providing accurate and precise models for testing and analysis, facilitating the development of personalized cancer therapies.
SHINE
Series B in 2018
SHINE develops and deploys fusion-based technology to produce medical isotopes and neutron sources. Its processes generate molybdenum-99, a precursor to technetium-99m used in diagnostic imaging, and lutetium-177 for diagnostic and therapeutic use, along with iodine-131 and iodine-125 for thyroid treatment and brachytherapy, and xenon-133 for lung and brain imaging. The company’s systems also provide neutron sources for industrial imaging, radiation-effects testing, and fusion materials research. In addition to medical isotopes, SHINE aims to recycle nuclear waste and advance fusion power as a source of clean energy. The business serves health care and industrial customers worldwide. SHINE is based in Janesville, Wisconsin, with an office in Alkmaar, Netherlands.
American Gene Technologies International
Series D in 2018
American Gene Technologies International is a gene and cell therapeutics company developing a lentiviral platform for broad applications across infectious diseases, immuno-oncology, monogenic disorders, and regenerative medicine. It pursues HIV cure strategies, including a lead candidate for functional cure, and an immuno-oncology approach that stimulates gamma-delta T cells to target solid tumors. The company also develops a therapeutic approach for Phenylketonuria by expressing phenylalanine hydroxylase, using proprietary viral vector and gene therapy technologies. Founded in 2007 and based in Rockville, Maryland, AGT focuses on translating its platform into therapies that aim to cure diseases rather than merely treat them.
Innoblative Designs
Venture Round in 2018
Innoblative Designs, Inc. is a medical device company based in Chicago, Illinois, with an additional office in Mansfield, Massachusetts. Established in 2013, the company specializes in the development of innovative electrosurgical devices aimed at enhancing surgical procedures. One of its key products is Sira™, a Saline-assisted Intraoperative Radiofrequency Ablation device. This device utilizes bipolar current to create a controlled zone of ablation during surgery, facilitating the coagulation and ablation of soft tissue beds. Sira's unique design features a saline microinfusion system that ensures optimal contact with target tissue, allowing it to be seamlessly integrated with existing electrosurgical generators in operating rooms. This makes Sira an accessible and effective option for surgeons seeking to improve intraoperative ablation techniques.
Siris Medical
Venture Round in 2018
Founded in 2013, Siris Medical specializes in artificial intelligence-driven treatment decision support systems for radiation therapy in cancer patients. Its flagship product, InsightRT Software Suite, enables efficient management of patient data and offers tools like QuickMatch and PlanMD for personalized treatment recommendations.
NeuSpera Medical
Series B in 2018
NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.
Equillium
Seed Round in 2018
Equillium is a clinical-stage biotechnology company focused on developing novel therapeutics for autoimmune and immuno-inflammatory disorders with high unmet medical need. Its lead candidate, EQ001 (Itolizumab), is a first-in-class monoclonal antibody that selectively targets the CD6 immune receptor to downregulate pathogenic effector T cells while preserving regulatory T cells by modulating the CD6-ALCAM signaling pathway. The approach targets a range of immuno-inflammatory diseases, including graft-versus-host disease, asthma, uveitis, colitis, lupus, and multiple sclerosis. Equillium aims to advance its programs through clinical development and may commercialize products independently or through partnerships or strategic transactions to monetize its pipeline.
Groups Recover Together
Venture Round in 2017
Groups Recover Together, Inc. is a healthcare provider specializing in the treatment of opioid addiction through a combination of medication-assisted treatment and therapeutic services. Founded in 2014 and headquartered in Manchester, New Hampshire, the company operates private clinics across several states, including California, Indiana, Maine, Michigan, West Virginia, and North Carolina. Its services include the administration of Suboxone (buprenorphine), weekly group therapy sessions, and personalized support to help patients set and achieve life goals. By fostering a supportive community, Groups Recover Together aims to empower individuals to regain control of their lives and pursue long-term recovery from opiate use disorder.
Celularity
Venture Round in 2017
Celularity is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies targeting various diseases, including cancer, infectious, and degenerative conditions.
Harbor MedTech
Series C in 2017
Harbor MedTech is a regenerative medicine company focused on developing and commercializing tissue regeneration products for wound care, hernia and joint repair, and related surgical applications. Its product portfolio includes Architect, an extracellular collagen matrix used to treat partial- and full-thickness skin wounds such as diabetic ulcers and venous ulcers; and EPMatrix, a collagen scaffold for soft tissue repair and reinforcement. The company leverages its BriDGE platform to create solutions across breast reconstruction, hernia repair, and orthopedic and dermatologic applications. It also markets NeuvoCell, a wound therapy for chronic wounds. Harbor MedTech, founded in 2010, is headquartered in Irvine, California.
Innoblative Designs
Venture Round in 2017
Innoblative Designs, Inc. is a medical device company based in Chicago, Illinois, with an additional office in Mansfield, Massachusetts. Established in 2013, the company specializes in the development of innovative electrosurgical devices aimed at enhancing surgical procedures. One of its key products is Sira™, a Saline-assisted Intraoperative Radiofrequency Ablation device. This device utilizes bipolar current to create a controlled zone of ablation during surgery, facilitating the coagulation and ablation of soft tissue beds. Sira's unique design features a saline microinfusion system that ensures optimal contact with target tissue, allowing it to be seamlessly integrated with existing electrosurgical generators in operating rooms. This makes Sira an accessible and effective option for surgeons seeking to improve intraoperative ablation techniques.
Pelvalon
Venture Round in 2016
Pelvalon is a medical device company focused on improving the quality of life for women experiencing fecal incontinence. The company develops innovative, non-surgical therapy devices aimed at addressing the challenges associated with pelvic and bowel health. By providing a treatment option that does not involve drugs or hormones, Pelvalon offers a solution for women suffering from accidental bowel leakage, helping them regain bowel control and enhance their overall well-being.
Compass Therapeutics
Series A in 2016
Founded in 2014, Compass Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics to treat solid tumors and hematological malignancies. Its pipeline includes CTX-471, an agonistic antibody of CD137 for immune cell activation, currently in Phase I trials; CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, in IND-enabling studies; and CTX-009, a bispecific antibody inhibiting DLL4 and VEGF-A signaling, completed Phase I and is in Phase Ib combination with chemotherapy.
Groups Recover Together
Series B in 2015
Groups Recover Together, Inc. is a healthcare provider specializing in the treatment of opioid addiction through a combination of medication-assisted treatment and therapeutic services. Founded in 2014 and headquartered in Manchester, New Hampshire, the company operates private clinics across several states, including California, Indiana, Maine, Michigan, West Virginia, and North Carolina. Its services include the administration of Suboxone (buprenorphine), weekly group therapy sessions, and personalized support to help patients set and achieve life goals. By fostering a supportive community, Groups Recover Together aims to empower individuals to regain control of their lives and pursue long-term recovery from opiate use disorder.
Compass Therapeutics
Series A in 2015
Founded in 2014, Compass Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics to treat solid tumors and hematological malignancies. Its pipeline includes CTX-471, an agonistic antibody of CD137 for immune cell activation, currently in Phase I trials; CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, in IND-enabling studies; and CTX-009, a bispecific antibody inhibiting DLL4 and VEGF-A signaling, completed Phase I and is in Phase Ib combination with chemotherapy.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.